Voclosporin for Induction Treatment of Lupus Nephritis in a Predominantly Black Patient Population: A Case Series (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #SA-PO0857; Pres time: Nov 8, 2025; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "Its efficacy and safety were demonstrated in the AURORA-1 trial in combination with mycophenolate mofetil and steroids for induction of lupus nephritis and long-term maintenance in the AURORA-2 trial, showing a 32% complete renal response (CRR) at 24 weeks. Voclosporin was well-tolerated, with only one patient discontinuing therapy. These findings suggest voclosporin may be particularly beneficial for LN patients with nephrotic-range proteinuria and in pure class V. Further evaluation of 52-week outcomes and long-term maintenance is warranted."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Paul Kim; Frehiywot K Ayele; Spencer A. King; Ivanna Ward; Jason Cobb
|